| Diffuse Large B-Cell Lymphoma
Polivy vs Zynlonta
Side-by-side clinical, coverage, and cost comparison for diffuse large b-cell lymphoma.Deep comparison between: Polivy vs Zynlonta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZynlonta has a higher rate of injection site reactions vs Polivy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zynlonta but not Polivy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Polivy
Zynlonta
At A Glance
IV infusion
Every 21 days
CD79b-directed antibody-drug conjugate
IV infusion
Every 3 weeks
CD19-directed antibody-drug conjugate
Indications
- Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
Dosing
Diffuse Large B-Cell Lymphoma (previously untreated), HGBL 1.8 mg/kg IV infusion every 21 days for 6 cycles in combination with rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP); administer initial dose over 90 minutes, subsequent doses may be given over 30 minutes if tolerated.
Diffuse Large B-Cell Lymphoma (relapsed or refractory) 1.8 mg/kg IV infusion every 21 days for 6 cycles in combination with bendamustine and a rituximab product; administer initial dose over 90 minutes, subsequent doses may be given over 30 minutes if tolerated.
Diffuse Large B-Cell Lymphoma 0.15 mg/kg IV over 30 minutes every 3 weeks for 2 cycles, then 0.075 mg/kg every 3 weeks for subsequent cycles; premedicate with dexamethasone 4 mg orally or IV twice daily for 3 days beginning the day before administration.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Peripheral neuropathy, neutropenia, thrombocytopenia, anemia, fatigue, diarrhea, nausea, constipation, alopecia, mucositis, pyrexia, decreased appetite
Serious Peripheral neuropathy, infusion-related reactions, myelosuppression, serious and opportunistic infections, progressive multifocal leukoencephalopathy, tumor lysis syndrome, hepatotoxicity, infusion site extravasation injury
Most common (>20%) Thrombocytopenia, increased GGT, neutropenia, anemia, hyperglycemia, transaminase elevation, fatigue, hypoalbuminemia, rash, edema, nausea, musculoskeletal pain.
Serious Febrile neutropenia, pneumonia, edema, pleural effusion, sepsis.
Postmarketing Telangiectasia, cutaneous collagenous vasculopathy, blister, rash vesicular.
Pharmacology
Polatuzumab vedotin-piiq is a CD79b-directed antibody-drug conjugate; the monoclonal antibody binds CD79b on B cells, is internalized, and releases MMAE intracellularly via lysosomal protease cleavage, where MMAE binds microtubules to inhibit cell division and induce apoptosis in dividing B cells.
Loncastuximab tesirine-lpyl is a CD19-directed antibody-drug conjugate (ADC); upon binding to CD19, the conjugate is internalized and releases SG3199, a PBD dimer alkylating agent that forms cytotoxic DNA interstrand crosslinks, inducing cell death in B-lineage cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Polivy
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Zynlonta
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Polivy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Zynlonta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Polivy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Zynlonta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableADVANCING Patient Support Patient Assistance Program: Zynlonta
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PolivyView full Polivy profile
ZynlontaView full Zynlonta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.